Pharmacovigilance of herbal medicine

Journal of Ethnopharmacology

Volumn 140, Issue 3, 2012, Pages 513-518

  Shaw, Debbie ^a   Graeme, Ladds ^b   Pierre, Duez ^c   Elizabeth, Williamson ^d   Kelvin, Chan ^e,f  

^a GUY S HOSPITAL   (United Kingdom)

^b Pharsafer   (United Kingdom)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITY OF READING   (United Kingdom)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Drug safety; Herbal medicine; Pharmacovigilance

Indexed keywords

ARISTOLOCHIC ACID; HERBACEOUS AGENT; SIBUTRAMINE; SILDENAFIL; STEROID;

ARISTOLOCHIA; CARDIOTOXICITY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG NOMENCLATURE; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; GENOTOXICITY; HERB DRUG INTERACTION; HERBAL MEDICINE; HERBAL PRACTITIONER; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LIVER TOXICITY; MEDICAL SPECIALIST; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PRESCRIPTION EVENT MONITORING; REVIEW; TERATOGENICITY; UNITED STATES;

EID: 84859008077     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2012.01.051     Document Type: Article

References (33)

1. Barnes, J., Mills, S.Y., Abbot, N.C., et al., 1998. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. British Journal of Clinical Pharmacology 45, 496-500. (Pubitemid 28228730)
2. Barnes, J., 2003. Pharmacovigilance of herbal medicines: A UK perspective. Drug Safety 26, 829-851.
3. CIOMS Working Group III, 1995. Good safety information practices. In: Guidelines for Preparing Core Clinical Safety Information on Drugs. WHO, Geneva.
4. Delgoda, R., Ellington, C., Barrett, S., Gordon, N., Clarke, N., Younger, N., 2004. The practice of polypharmacy involving herbal and prescription medicines in the treatment of diabetes mellitus, hypertension and gastrointestinal disorders in Jamaica. West Indian Medical Journal 53, 400-405. (Pubitemid 40485195)
5. Dennehy, C.E., Tsourounis, C., Horn, A.J., 2005. Dietary supplement-related adverse events reported to the California poison control system. American Journal of Health-System Pharmacy 62, 1476-1482. (Pubitemid 41008861)
6. DynPage, 2011. http://www.who-umc.org/DynPage.aspx?id=97218&mn1= 7347& mn2=7252.
7. Edwards, I.R., Aronson, J.K., 2000. Adverse drug reactions: definitions, diagnosis and management. Lancet 356, 1255-1259.
8. Gagnier, J., Boon, H., Rochon, P., Moher, D., Barnes, J., Bombardier, C., for the CONSORT Group, 2006. Controlled trials evaluating herbal interventions: implementing the consort statement. Drug Safety 29, 911-1010.
9. Gardiner, P., Sarma, D., Low Dog, T., Barrett, M., Chavez, M., Ko, R., Mahady, G., Marles, R., Pellicore, L., Giancaspro, G., 2008. The state of dietary supplement adverse event reporting in the United States. Pharmacoepidemiology and Drug Safety 17, 962-970.
10. Giveon, S.M., Liberman, N., Klang, S., Kahan, E., 2004. Are people who use natural drugs aware of their potentially harmful side effects and reporting to family physician. Patient Education Counsel 53, 5-11. (Pubitemid 38519979)
11. Goldstein, L.H., Elias, M., Ron-Avraham, G., Biniaurishvili, B.Z., Madjar, M., Kamargash, I., Braunstein, R., Berkovitch, M., Golik, A., 2007. Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards. British Journal of Clinical Pharmacology 64, 373-380. (Pubitemid 47283856)
12. Gryzlak, B.M., Wallace, R.B., Zimmerman, M.B., Nisly, N., 2007. National surveillance of herbal dietary supplement exposures: the poison control center experience. Pharmacoepidemiology and Drug Safety 16, 947-957. (Pubitemid 47422842)
13. Hazell, L., Shakir, S.A.W., 2006. Under reporting of adverse drug reactions: a systematic review. Drug Safety 29, 385-396.
14. Heinrich, M., Chan, J., Wanke, S., Neinhuis, C., Simmonds, M., 2009. Local uses of Aristolochia species and content of nephrotoxic aristolochic acids 1 and 2 - a global assessment based on bibliographic sources. Journal of Ethnopharmacology 125, 108-144.
15. Ipsos Mori, 2008. Public Perceptions of Herbal Medicines General Public Qualitative and Quantitative Research, http://www.mhra.gov.uk/home/groups/ commspo/ documents/news/con036073.pdf (accessed October 2011).
16. Jacobsson, I., Jonsson, A., Gerden, B., Hagg, S., 2009. Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiology and Drug Safety 18, 1039-1047.
17. Kelly, W.N., Arellano, F.M., Barnes, et al., 2007. Guidelines for submitting adverse event reports for publication. Drug Safety 30, 367-373. (Pubitemid 46740334)
18. Lemy, A., Wissing, K.M., Rorive, S., Ziotta, A., Roumeguere, T., Muniz Martinez, M.C., Decaestecker, C., Salmon, I., Abramowicz, D., Vanherweghem, J.L., Nortier, J., 2008. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage arisotolochic acid nephropathy: a case series with 15-year follow up. American Journal of Kidney Diseases 51, 471-477. (Pubitemid 351273477)
19. Loew, D., Kaszkin, M., 2002. Approaching the problem of bioequivalence of herbal medicinal products. Phytotherapy Research 16, 705-711. (Pubitemid 135752575)
20. Mann, R.D., Andrews, E.F. (Eds.), 2002. Pharmacovigilance. Wiley, Chichester.
21. McLernon, D.J., Bond, C.M., Hannaford, P.C., et al., 2010. Adverse drug reaction reporting in the UK. Drug Safety 33, 775-786.
22. McRae, C.A., Agarwal, K., Mutimer, D., Bassendine, M.F., 2002. Hepatitis associated with Chinese herbs. European Journal of Gastroenterology and Hepatology 14, 559-562. (Pubitemid 34518190)
23. Menniti-Ippolito, F., Mazzanti, G., Santuccio, C., Moro, P., Calapai, G., Firenzuoli, Valeri, F., Raschetti, R., 2008. Surveillance of suspected adverse reactions to natural health products in Italy. Pharmacoepidemiology and Drug Safety 17, 626-635. (Pubitemid 351982769)
24. Nortier, J., Vanherweghem, J.L., 2007. For patients taking herbal therapy - lessons from aristolochic acid nephropathy. Nephrology Dialysis and Transplantation 22, 1512-1517. (Pubitemid 47073747)
25. Perharic, L., Shaw, D., Leon, C., De Smet, P.A., Murray, V.S., 1995. Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Veterinary and Human Toxicology 37, 562-566.
26. Reginster, F., Jadoul, M., van Ysersele de Strihou, C., 1995. Chinese herbs nephropathy presentation, natural history and fate after transplantation. Nephrology Dialysis and Transplantation 10, 157-160.
27. Saokaew, S., Suwankesawong, W., Permsuwann, U., et al., 2011. Safety of herbal products in Thailand. Drug Safety 34, 339-350.
28. Shaw, D., 2010a. Toxicological risks of Chinese herbs. Planta Medica 76, 2012-2018.
29. Shaw, D., 2010b. Investigation of liver toxicity of Chinese herbal medicine: pilot case-control study. Drug Safety 33, 918-919.
30. Strandell, J., Caster, O., Bate, A., Norén, G.N., Edwards, I.R., 2011. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Safety 34, 253-266.
31. UMC. 2011. 〈http://www.who-umc.org/graphics/24727.pdf〉 (accessed 24.10.11.).
32. World Health Organisation, 2004. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. WHO, Geneva.
33. Williamson, E.M., Driver, S., Baxter, K. (Eds.), 2009. Stockley's Herbal Medicines Interactions. Pharmaceutical Press, UK.